Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Retinal Neuro-vascular Coupling in Patients With Neurodegenerative Disease

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02663531
Recruitment Status : Recruiting
First Posted : January 26, 2016
Last Update Posted : February 20, 2020
Sponsor:
Information provided by (Responsible Party):
Gerhard Garhofer, Medical University of Vienna

Study Description
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
Alzheimer´s disease (AD) in one of the most important causes of dementia and poses a considerable challenge in health care. Today, criteria for the diagnosis and the follow up of patients with AD mainly rely either on subjective tests or invasive methods. This limits the general applicability of the latter test for population screening and underlines the need for the identification of easily accessible tools for the identification of high-risk subjects. Because of its unique optical properties, the eye offers the possibility of the non-invasive assessment of both structural and functional alterations in neuronal tissue. As the neuro-retina is part of the brain, it does not come as a surprise that neuro-degenerative changes in the brain are accompanied by structural and possibly also functional changes in the neuro-retina and the ocular vasculature. The current study seeks to test the hypothesis that beside the known anatomical changes, also functional changes can be detected in the retina of patients with AD. For this purpose, flicker light induced hyperemia will be measured in the retina as a functional test to assess the coupling between neural activity and blood flow. Further, structural parameters such as retinal nerve fiber layer thickness and function parameters such as ocular blood flow and retinal oxygenation will be assessed and compared to age and sex matched controls.

Condition or disease Intervention/treatment Phase
Mild Cognitive Impairment Alzheimer Disease Healthy Device: DVA Device: FDOCT Device: Pattern ERG Device: Optical Coherence Tomography Not Applicable

Study Design
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 150 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Basic Science
Official Title: Retinal Neuro-vascular Coupling in Patients With Neurodegenerative Disease
Actual Study Start Date : September 27, 2016
Estimated Primary Completion Date : December 2020
Estimated Study Completion Date : December 2020

Resource links provided by the National Library of Medicine


Arms and Interventions
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm Intervention/treatment
Experimental: Mild cognitive impairment
Patients with mild cognitive impairment
 Device: DVA
Other Name: Dynamic Vessel Analyzer

Device: FDOCT
Other Name: Fourier Domain Color Doppler Optical Coherence Tomography

Device: Pattern ERG
Device: Optical Coherence Tomography
Experimental: Alzheimer Disease
Patients with Alzheimer Disease
 Device: DVA
Other Name: Dynamic Vessel Analyzer

Device: FDOCT
Other Name: Fourier Domain Color Doppler Optical Coherence Tomography

Device: Pattern ERG
Device: Optical Coherence Tomography
Experimental: Healthy
Healthy volunteers
 Device: DVA
Other Name: Dynamic Vessel Analyzer

Device: FDOCT
Other Name: Fourier Domain Color Doppler Optical Coherence Tomography

Device: Pattern ERG
Device: Optical Coherence Tomography


Outcome Measures
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. Flicker induced increase in retinal blood flow [ Time Frame: 1 day ]

Eligibility Criteria
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   50 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

Inclusion criteria for healthy subjects

  • Men and women aged over 50 years
  • Non-smokers
  • Normal findings in the medical history unless the investigator considers an abnormality to be clinically irrelevant
  • Normal ophthalmic findings, ametropia < 6 Dpt

Inclusion criteria for patients with AD:

  • Men and women aged over 50 years
  • Normal ophthalmic findings, ametropia < 6 Dpt.

  • Confirmed diagnosis of probable AD of mild to moderate degree defined as:

    1. Diagnosis of probable Alzheimer's disease based on the NINCDS/ADRDA criteria
    2. Assessing the severity of Alzheimer's disease of mild to moderate degree by the Mini Mental State Examination (MMSE). AD of mild to moderate degree has been confirmed if the MMSE score is in the range of 20 to 26 inclusive
  • Hachinski Ischemia Scale is used to try and distinguish AD from multi-infarct dementia. A score of ≤ 4 suggests AD Informed consent capability
  • Adequate visual and auditory acuity to allow neuropsychological testing and participation in the ocular blood flow measurements
  • A potential participant has to be on stable doses of all medications he/she is taking because of consisting illnesses according to medical history (except AD therapy itself which will be recorded separately) for at least 30 days prior inclusion, if considered relevant by the investigator.

Inclusion criteria for patients with mild cognitive impairment:

  • Men and women aged over 50 years
  • Normal ophthalmic findings, ametropia < 6 Dpt.

  • Diagnosis of probable mild cognitive impairment (MCI) defined as:

    1. memory complaint, corroborated by an informant
    2. abnormal memory function, documented by delayed recall of one paragraph from the Logical Memory II subtest of the Wechsler Memory Scale-Revised (cutoff scores: ≤8 for ≥16 years of education; ≤4 for 8 to 15 years of education; and ≤2 for 0 to 7 years of education [the maximum number of paragraph items possible to correctly recall is 25])
    3. normal general cognitive function, as determined by a clinician's judgment based on a structured interview with the patient and an informant (Clinical Dementia Rating [CDR]) and a Mini-Mental State Examination (MMSE) score greater than 26
    4. no or minimal impairment in activities of daily living (ADLs), as determined by a clinical interview with the patient and informant
    5. not sufficiently impaired, cognitively and functionally, to meet the NINCDS/ADRDA criteria, as judged by an experienced AD research clinician
  • Hachinski Ischemia Scale is used to try and distinguish MCI from multi-infarct dementia. A score of ≤ 4 suggests MCI Informed consent capability
  • Adequate visual and auditory acuity to allow neuropsychological testing and participation in the ocular blood flow measurements
  • A potential participant has to be on stable doses of all medications he/she is taking because of consisting illnesses according to medical for at least 30 days prior inclusion, if considered relevant by the investigator.

Exclusion Criteria for patients:

  • Presence or history of a severe medical condition other than cognitive impairment as judged by the clinical investigator
  • Untreated Arterial hypertension
  • History or family history of epilepsy
  • Presence of any abnormalities preventing reliable measurements in the study eye as judged by the investigator
  • Best corrected visual acuity < 0.5 Snellen
  • Ametropia greater than 6 Dpt
  • pregnancy or planned pregnancy
  • Major psychiatric disorder (e.g. schizophrenia), if considered relevant by the investigator
  • Significant neurological disease other than AD or MCI, if considered relevant by the investigator
  • Alcoholism or substance abuse

Exclusion criteria for healthy volunteers:

  • Presence or history of a severe medical condition as judged by the clinical investigator
  • Untreated Arterial hypertension
  • History or family history of epilepsy
  • Presence of any abnormalities preventing reliable measurements in the study eye as judged by the investigator
  • Family history of AD
  • Best corrected visual acuity < 0.5 Snellen
  • Ametropia 6 Dpt
  • Pregnancy or planned pregnancy
Contacts and Locations
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02663531


Contacts
Layout table for location contacts
Contact: Gerhard Garhöfer, MD 0043140400 ext 29810 gerhard.garhoefer@medunwien.ac.at

Locations
Layout table for location information
Austria
Department of Clinical Pharmacology, Medical University of Vienna Recruiting
Vienna, Austria, 1090
Contact: Gerhard Garhöfer, MD    +43 (1) 40400 ext 29810    gerhard.garhoefer@meduniwien.ac.at   
Principal Investigator: Gerhard Garhöfer, MD         
Sponsors and Collaborators
Medical University of Vienna
Investigators
Layout table for investigator information
Principal Investigator: Gerhard Garhöfer, MD Department of Clinical Pharmacology, Medical University of Vienna
More Information
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Layout table for additonal information
Responsible Party: Gerhard Garhofer, Assoc. Prof. PD Dr., Medical University of Vienna
ClinicalTrials.gov Identifier: NCT02663531    
Other Study ID Numbers: OPHT-180515
First Posted: January 26, 2016    Key Record Dates
Last Update Posted: February 20, 2020
Last Verified: February 2020
Additional relevant MeSH terms:
Layout table for MeSH terms
Alzheimer Disease
Neurodegenerative Diseases
Cognitive Dysfunction
Dementia
Brain Diseases
Central Nervous System Diseases
 Nervous System Diseases
Tauopathies
Neurocognitive Disorders
Mental Disorders
Cognition Disorders